In this issue:
Acute HEV rare in acute liver failure
A new approach for HCV vaccine development?
Concomitant PPI use with ledipasvir/ sofosbuvir
Complement-mediated preferential binding of HCV to B cells
A human MAb prevents acute HCV in mice
Cellular immunity against the fulllength HEV virus
Elbasvir/grazoprevir vs sofosbuvir + PEG-IFN/ribavirin in HCV
Ledipasvir/sofosbuvir-based treatments in the real world
Serum Siglec-7 linked to liver disease in chronic HCV
Direct-acting antivirals effective in HCV + cirrhosis
Please login below to download this issue (PDF)